Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fospropofol disodium vs midazolam plus remifentanil for sedation in mild–moderate ARDS
ChiCTR2500098766Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fospropofol disodium in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: 28 days of mechanical ventilation-free time. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
fospropofol disodium
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2500098766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098766.